A different approach was followed by Wang et al. [39], who included clinical trials testing different agents and, among these, clinical trials of EGFR-TKIs in NSCLC patients unselected for EGFR status, which could interact with gender and act as a confounder. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.